Progress in stratified medicine for genetic cancer sub-groups

19 August 2011

Trials of personalised (or more accurately, stratified) medicines targeted specifically at specific sub-populations of patients will become increasingly common in coming years, especially in cancer. The drug vemurafenib (PLX4032) has just been approved in the US for the treatment of advanced melanomas that have mutations in the BRAF gene (see previous news). 

More from us

Genomics and policy news